目的 采用Meta分析考察西达本胺联合标准化疗治疗外周T细胞淋巴瘤的临床疗效。方法 搜索了中国知网、万方、维普、Web of Science、PubMed、Cochrane Library、Embase等数据库，检索文献发表时间为从数据库建库到2023年6月的西达本胺联合标准化疗治疗外周T细胞淋巴瘤的试验，应用Cochrane中心提供的Revman 5.4软件对数据进行统计学处理分析。结果 筛选符合标准的文献为10篇，共494例患者。西达本胺在外周T细胞淋巴瘤治疗中可显著改善完全缓解率、客观缓解率、1年生存率、1年无进展生存率，与标准化疗间的差异具有统计学意义。结论 对于外周T细胞淋巴瘤患者，西达本胺联合化疗在完全缓解率、客观缓解率、1年生存率、1年无进展生存率均优于单纯化疗。

Objective To study the efficacy of chidamide combined with standard chemotherapy in treatment of peripheral T-cell lymphoma by Meta-analysis. Methods Trials of chidamide combined with standard chemotherapy in treatment of peripheral T-cell lymphoma were collected by retrieval from CNKI, Wanfang, VIP, Web of Science, PubMed, Cochrane Library, Embase, etc. The search time was from the establishment to June, 2023. The data were statistical analyzed by Cochrane RevMan 5.4. Results A total of 10 literatures with a total of 494 cases. Compared with standard chemotherapy, chidamide combined with standard chemotherapy can significantly improve CR, ORR, one-year PFS, and one-year OS in treatment of peripheral T-cell lymphoma with a statistically significant difference. Conclusion Compared with standard chemotherapy, chidamide combined with standard chemotherapy has better complete response rate, objective response rate, one-year survival rate, and one-year progression free survival rate in treatment of peripheral T-cell lymphoma.

R979.1

江苏省“六大人才高峰”高层次人才选拔培养计划资助项目(WSN-019);南京市科技计划项目(201803043);南京医科大学研究生教育研究专项2021年度重点项目(2021YJS-ZD016)